Top Story

Nivolumab demonstrates superiority to chemotherapy for advanced melanoma

March 31, 2015

Nivolumab was associated with a greater objective response rate and an improved toxicity profile compared with chemotherapy in patients with advanced melanoma who had progressed after anti-cytotoxic T-lymphocyte antigen-4 treatment, according to the results of a randomized, open-label, phase 3 trial.

“Nivolumab is clearly a superior choice in term of response rate and toxicity to chemotherapy for patients who have failed prior ipilimumab, or ipilimumab and a BRAF inhibitor if the patient is BRAF-mutated,” study researcher Jeffrey S. Weber, MD, PhD, of the Moffitt Cancer Center in Tampa, Florida, told HemOnc Today.

Robert L. Coleman, MD Meeting News Coverage

Bevacizumab plus chemotherapy improves OS in recurrent ovarian cancer

March 31, 2015
The addition of bevacizumab to a standard chemotherapy regimen conferred a median 5-month survival improvement among women with ovarian cancer, according to results of a…
David Weinberg In the Journals

AGA guideline recommends change in diagnosis, management of asymptomatic pancreatic cysts

March 31, 2015
The American Gastroenterological Association has released a new guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts, which recommends…
FDA News

FDA strengthens warning, changes prescribing instructions for Feraheme

March 31, 2015
The FDA approved the addition of a boxed warning and updated the prescribing instructions for the anemia drug ferumoxytol, according to a press release from the…
FDA News

FDA approves Jadenu for chronic iron overload

March 31, 2015
The FDA announced the approval of Jadenu tablets for the treatment of certain patients with chronic iron overload, according to a press release from the drug’s…
More News Headlines »
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
thumbnail for video 4126759064001

Solid organ transplant recipients at higher risk for skin cancer

March 22, 2015
SAN FRANCISCO – In this video, Sarah Tuttleton Arron, MD, PhD, FAAD, discusses her research on mortality from…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
morganatic-roan